Q4 EPS Estimates for Eton Pharmaceuticals Raised by B. Riley

Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) - Research analysts at B. Riley raised their Q4 2025 EPS estimates for shares of Eton Pharmaceuticals in a research report issued to clients and investors on Sunday, April 27th. B. Riley analyst M. El-Saadi now expects that the company will earn $0.33 per share for the quarter, up from their previous estimate of $0.25. B. Riley has a "Buy" rating and a $24.00 price target on the stock. The consensus estimate for Eton Pharmaceuticals' current full-year earnings is ($0.14) per share.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($0.02) EPS for the quarter, hitting the consensus estimate of ($0.02). The company had revenue of $11.65 million for the quarter, compared to the consensus estimate of $10.53 million. Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%.

A number of other research firms also recently issued reports on ETON. HC Wainwright reissued a "buy" rating and set a $33.00 price target on shares of Eton Pharmaceuticals in a research report on Wednesday, March 19th. Craig Hallum lifted their price objective on shares of Eton Pharmaceuticals from $23.00 to $26.00 and gave the stock a "buy" rating in a research note on Wednesday, March 19th.

Eton Pharmaceuticals Trading Up 2.2 %

Shares of NASDAQ ETON traded up $0.37 during trading hours on Tuesday, reaching $17.34. The stock had a trading volume of 239,854 shares, compared to its average volume of 180,687. The business's fifty day moving average price is $14.21 and its two-hundred day moving average price is $13.19. The firm has a market cap of $465.02 million, a price-to-earnings ratio of -78.82 and a beta of 1.34. Eton Pharmaceuticals has a 52-week low of $3.18 and a 52-week high of $18.41.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Nantahala Capital Management LLC boosted its holdings in Eton Pharmaceuticals by 12.0% in the 4th quarter. Nantahala Capital Management LLC now owns 1,118,483 shares of the company's stock worth $14,898,000 after buying an additional 119,750 shares during the last quarter. Westside Investment Management Inc. increased its position in shares of Eton Pharmaceuticals by 5.7% during the third quarter. Westside Investment Management Inc. now owns 618,675 shares of the company's stock worth $3,711,000 after purchasing an additional 33,275 shares in the last quarter. Mink Brook Asset Management LLC purchased a new position in Eton Pharmaceuticals in the 4th quarter valued at $6,071,000. Cannell Capital LLC acquired a new stake in Eton Pharmaceuticals during the 4th quarter worth $5,079,000. Finally, Parkman Healthcare Partners LLC raised its position in shares of Eton Pharmaceuticals by 6.4% in the fourth quarter. Parkman Healthcare Partners LLC now owns 276,890 shares of the company's stock valued at $3,688,000 after buying an additional 16,664 shares during the last quarter. 27.86% of the stock is owned by institutional investors and hedge funds.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.